Prothena Corporation PLC Company Profile (NASDAQ:PRTA)

About Prothena Corporation PLC (NASDAQ:PRTA)

Prothena Corporation PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRTA
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.5 billion
  • Outstanding Shares: 38,020,000
Average Prices:
  • 50 Day Moving Avg: $57.39
  • 200 Day Moving Avg: $53.95
  • 52 Week Range: $40.58 - $68.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.05
  • P/E Growth: 0.83
Sales & Book Value:
  • Annual Revenue: $1.05 million
  • Price / Sales: 2,376.79
  • Book Value: $13.07 per share
  • Price / Book: 5.02
  • EBIDTA: ($157,960,000.00)
  • Net Margins: -16,012.49%
  • Return on Equity: -39.67%
  • Return on Assets: -33.19%
  • Current Ratio: 15.27%
  • Quick Ratio: 15.27%
  • Average Volume: 308,240 shs.
  • Beta: 2.58
  • Short Ratio: 20.11
Frequently Asked Questions for Prothena Corporation PLC (NASDAQ:PRTA)

What is Prothena Corporation PLC's stock symbol?

Prothena Corporation PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Corporation PLC's earnings last quarter?

Prothena Corporation PLC (NASDAQ:PRTA) posted its earnings results on Tuesday, May, 9th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.33. The firm had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.26 million. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The company's revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.81) earnings per share. View Prothena Corporation PLC's Earnings History.

Where is Prothena Corporation PLC's stock going? Where will Prothena Corporation PLC's stock price be in 2017?

12 equities research analysts have issued 1-year target prices for Prothena Corporation PLC's shares. Their forecasts range from $65.00 to $100.00. On average, they anticipate Prothena Corporation PLC's share price to reach $77.45 in the next twelve months. View Analyst Ratings for Prothena Corporation PLC.

What are analysts saying about Prothena Corporation PLC stock?

Here are some recent quotes from research analysts about Prothena Corporation PLC stock:

  • 1. According to Zacks Investment Research, "The narrower-than-expected loss in the first quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's elicense agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments.The company’s shares have outperformed the Medical/Biomedical Genetics industry in the past one year. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (5/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "Sticking to their knitting. In prior experience, PRTA scientists developed monoclonal antibodies (MAbs) bapineuzumab and natalizumab (Tysabri) that targeted misfolded protein (beta amyloid) and prevented T cell trafficking, respectively." (4/12/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Corporation PLC's key competitors?

Who are Prothena Corporation PLC's key executives?

Prothena Corporation PLC's management team includes the folowing people:

  • Lars G. Ekman M.D. Ph.D., Independent Chairman of the Board
  • Gene G. Kinney Ph.D., President, Chief Executive Officer, Director
  • Tran B. Nguyen, Chief Financial Officer
  • Karin L. Walker CPA, Chief Accounting Officer, Controller
  • Wagner Zago, Chief Scientific Officer
  • Arthur W. Homan, Chief Legal Officer
  • Carol D. Karp, Chief Regulatory Officer
  • Martin Koller M.D., Chief Medical Officer
  • Tara Nickerson Ph.D., Chief Business Officer
  • K. Anders O. Harfstrand M.D., Ph.D., Director

Who owns Prothena Corporation PLC stock?

Prothena Corporation PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.09%), Handelsbanken Fonder AB (0.07%), Fisher Asset Management LLC (0.06%), Public Employees Retirement Association of Colorado (0.02%), Barometer Capital Management Inc. (0.02%) and Aperio Group LLC (0.01%). Company insiders that own Prothena Corporation PLC stock include Arthur W Homan, Christopher S Henney, Dale B Schenk, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Corporation PLC.

Who bought Prothena Corporation PLC stock? Who is buying Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Fisher Asset Management LLC, Barometer Capital Management Inc., Aperio Group LLC and Bank of Montreal Can. View Insider Buying and Selling for Prothena Corporation PLC.

How do I buy Prothena Corporation PLC stock?

Shares of Prothena Corporation PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena Corporation PLC's stock price today?

One share of Prothena Corporation PLC stock can currently be purchased for approximately $65.64.

MarketBeat Community Rating for Prothena Corporation PLC (NASDAQ PRTA)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Prothena Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Prothena Corporation PLC (NASDAQ:PRTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $77.45 (18.00% upside)

Analysts' Ratings History for Prothena Corporation PLC (NASDAQ:PRTA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$100.00MediumView Rating Details
7/6/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$70.00LowView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00HighView Rating Details
4/3/2017WedbushReiterated RatingOutperform$77.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/20/2016SunTrust Banks, Inc.Initiated CoverageBuy$75.00N/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$73.00N/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
7/18/2016Royal Bank Of CanadaReiterated RatingOutperform$95.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings History by Quarter for Prothena Corporation PLC (NASDAQ PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Prothena Corporation PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.07)
2018 EPS Consensus Estimate: ($5.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20174($1.20)($0.50)($0.87)
Q3 20174($1.62)($0.74)($1.29)
Q4 20174($1.96)($1.26)($1.55)
Q1 20181($1.39)($1.39)($1.39)
Q2 20181($1.36)($1.36)($1.36)
Q3 20181($1.18)($1.18)($1.18)
Q4 20181($1.07)($1.07)($1.07)
(Data provided by Zacks Investment Research)


Dividend History for Prothena Corporation PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.00View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.00View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Prothena Corporation PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Corporation PLC (NASDAQ:PRTA)
DateHeadline logoInsider Selling: Prothena Corporation PLC (NASDAQ:PRTA) Insider Sells 5,000 Shares of Stock - July 19 at 7:38 PM logo Brokerages Anticipate Prothena Corporation PLC (NASDAQ:PRTA) Will Announce Quarterly Sales of $12.87 Million - July 16 at 10:48 AM logoZacks: Analysts Expect Prothena Corporation PLC (NASDAQ:PRTA) Will Announce Earnings of -$1.02 Per Share - July 14 at 11:21 AM logoJefferies Group Weighs in on Prothena Corporation PLC's Q2 2017 Earnings (NASDAQ:PRTA) - July 13 at 10:50 AM logoProthena Corporation PLC (NASDAQ:PRTA) Now Covered by Jefferies Group LLC - July 10 at 5:26 PM logoDennis J. Selkoe Sells 3,500 Shares of Prothena Corporation PLC (PRTA) Stock - July 7 at 8:18 PM logoCommit To Purchase Prothena Corp At $45, Earn 15% Annualized Using Options - July 7 at 8:17 AM logoProthena Corporation PLC (NASDAQ:PRTA) Rating Reiterated by Oppenheimer Holdings, Inc. - July 6 at 11:02 AM logoProthena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease - July 6 at 8:05 AM logoPROTHENA CORPORATION PLC - July 6 at 8:05 AM logoProthena Corp. (PRTA) Commences Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease - July 6 at 8:05 AM logoProthena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease - July 6 at 8:05 AM logoProthena Corporation PLC (NASDAQ:PRTA) Given Consensus Rating of "Buy" by Brokerages - July 4 at 5:20 PM logoCarson Block Shorts Prothena on Drug Questions - June 30 at 4:25 AM logoFeared short seller Carson Block's next target is this biotech stock - June 30 at 4:25 AM logoMuddy Waters Shorts Prothena On Doubts Of Drug Candidate's Efficacy - June 30 at 4:25 AM logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : June 28, 2017 - June 29 at 6:16 AM logoPRTA Crosses Below Key Moving Average Level - June 27 at 7:26 PM logoResearch Analysts Issue Forecasts for Prothena Corporation PLC's FY2018 Earnings (PRTA) - June 26 at 8:00 AM logo$8.52 Million in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter - June 22 at 1:04 PM logo Analysts Anticipate Prothena Corporation PLC (PRTA) to Post -$1.09 Earnings Per Share - June 20 at 10:00 AM logoETFs with exposure to Prothena Corp. Plc : June 15, 2017 - June 16 at 9:04 AM logoProthena Corp. Plc – Value Analysis (NASDAQ:PRTA) : June 15, 2017 - June 16 at 9:04 AM logoProthena Corporation PLC (PRTA) Lifted to Hold at ValuEngine - June 15 at 8:10 PM logoProthena (PRTA) Down 5.8% Since Earnings Report: Can It Rebound? - June 14 at 8:37 AM logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : June 14, 2017 - June 14 at 8:37 AM logoProthena Corp. (PRTA) Confirms Wagner Zago PHD as Chief Scientific Officer - June 13 at 10:16 AM logoProthena Corp. (PRTA) Confirms Wagner Zago PHD as Chief Scientific Officer - - June 12 at 6:58 PM logoProthena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer - June 12 at 6:58 PM logoProthena Co. PLC (PRTA) Receives Average Rating of "Buy" from Brokerages - June 9 at 7:02 PM logoProthena Co. PLC (PRTA) Upgraded at ValuEngine - June 3 at 2:34 PM logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : May 29, 2017 - May 29 at 6:18 PM logoProthena Co. PLC (PRTA) Cut to "Strong Sell" at ValuEngine - May 27 at 3:14 PM logo Brokerages Expect Prothena Co. PLC (PRTA) Will Post Quarterly Sales of $8.52 Million - May 26 at 1:32 PM logoProthena Co. PLC (PRTA) Research Coverage Started at BTIG Research - May 19 at 7:42 AM logoProthena Co. PLC (PRTA) Rating Reiterated by Piper Jaffray Companies - May 17 at 7:50 PM logoProthena Announces Appointment of Sarah Noonberg, MD, PhD as ... - Nasdaq - May 17 at 8:26 AM logoETFs with exposure to Prothena Corp. Plc : May 15, 2017 - May 15 at 6:35 PM logoProthena Co. PLC (PRTA) Given Average Recommendation of "Buy" by Brokerages - May 15 at 2:46 PM logoProthena Co. PLC (PRTA) Lowered to "Hold" at Zacks Investment Research - May 15 at 12:22 PM logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : May 15, 2017 - May 15 at 9:48 AM logoEquities Analysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA) - May 15 at 7:30 AM logoProthena Co. PLC (PRTA) Forecasted to Earn Q2 2017 Earnings of ($1.20) Per Share - May 15 at 7:28 AM logoProthena Co. PLC (PRTA) Given a $70.00 Price Target at Oppenheimer Holdings Inc. - May 13 at 6:58 PM logoProthena Corp. Plc :PRTA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 8:07 PM logoAnalysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA) - May 12 at 8:35 AM logoProthena EPS of -$0.99 - May 12 at 12:51 AM logoSunTrust Banks Equities Analysts Increase Earnings Estimates for Prothena Co. PLC (PRTA) - May 11 at 3:42 PM logoWedbush Reaffirms Outperform Rating for Prothena Co. PLC (PRTA) - May 11 at 10:10 AM logoProthena Co. PLC (PRTA) Announces Earnings Results - May 10 at 7:40 PM



Prothena Corporation PLC (PRTA) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff